Epicondylitis News and Research

RSS

Poor cardiovascular health may contribute to the development of musculoskeletal disorders

People with higher risks of cardiovascular disease are significantly more likely to develop carpal tunnel syndrome, tennis elbow, golfer's elbow, and rotator cuff tendinitis, according to a new study involving researchers at the University of Utah and the Rocky Mountain Center for Occupational and Environmental Health.

5 Jun 2023

Botox can be an effective treatment for certain sports injuries

While botulinum toxin is commonly known as a cosmetic treatment for facial lines and wrinkles, a growing body of evidence suggests that "Botox" can also be an effective treatment for certain sports injuries and chronic pain conditions, according to a review in the June issue of Current Sports Medicine Reports, official journal of the American College of Sports Medicine.

9 Jun 2020

Review examines the role of biologic agents in management of shoulder and elbow problems

The utilization of stem cell therapies for augmentation of tissue healing has far outpaced the supporting scientific and clinical data, largely due to aggressive marketing that has led to widespread and often inappropriate use of cell therapy approaches in the United States.

1 Oct 2019

Ortho-ATI™ long term study showing effectiveness for tennis elbow published in prestigious American Journal of Sports Medicine

The publication provides evidence of the durability and long term positive effect of Orthocell’s Ortho-ATI™ tendon regeneration treatment for degenerate tendon injuries...

30 Apr 2015

Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI™ for treatment resistant tennis elbow

Regenerative medicine company Orthocell Limited has today released results from a long-term clinical study into its Ortho-ATI™ treatment for tennis elbow that provides evidence of the durability and long term success of this treatment.

25 Aug 2014

Research paper provides first evidence-based recommendations for using PRP in orthopaedic care

Platelet-rich plasma (PRP) has grabbed headlines in recent years for its role in helping some of sports' biggest stars return to play following injury -including golfer Tiger Woods, Super Bowl winner Hines Ward and NBA legend Kobe Bryant.

12 Dec 2013

Researchers analyze benefits of platelet-rich plasma therapy for tennis elbow

A procedure intended to help heal musculoskeletal injuries called platelet-rich plasma therapy, or P.R.P., has created a big buzz in sports medicine and the media in recent years. Tiger Woods reportedly received the procedure for a sore knee and Pittsburgh Steelers' Hines Ward used it for a sprained knee ligament just before playing a key role in the team's 2009 Super Bowl victory.

14 Nov 2013

Ultrasound boosts rheumatology clinical examination findings

Musculoskeletal ultrasound improves rheumatology diagnosis and guides treatment, say researchers who believe imaging should be performed alongside clinical examination.

21 Sep 2012

SANUWAVE’s ESWT stimulates proliferation of cambium cells for bone generation

SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.

6 Jun 2012

SANUWAVE first quarter revenues decrease 5% to $238,540

SANUWAVE Health, Inc. today reported financial results for the three months ended March 31, 2012 and provided a business update.

15 May 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

USPTO issues patent to SANUWAVE's new method that produces acoustic shock waves

SANUWAVE Health, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled "Method and Apparatus for Producing Shock Waves for Medical Applications."

18 Jan 2012

SANUWAVE PACE technology reverses negative effects of ischemic, reperfusion injuries

SANUWAVE Health, Inc., today reported publication of peer-reviewed, preclinical data conducted at Cleveland Clinic that demonstrate the ability of the Company's Pulsed Acoustic Cellular Expression (PACE®) technology to substantially decrease the detrimental effects of microcirculatory injury for certain ischemic (lack of blood flow) and reperfusion (restoration of blood flow) injuries.

11 Jan 2012

SANUWAVE receives U.S. patent titled, 'Device for the Application of Acoustic Shock Waves'

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,088,073, titled "Device for the Application of Acoustic Shock Waves."

7 Jan 2012

SANUWAVE Health third quarter revenues decrease 42% to $161,678

SANUWAVE Health, Inc. today reported financial results for the three and nine months ended September 30, 2011.

14 Nov 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

SANUWAVE second quarter revenues increase 40%

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

10 Aug 2011

USPTO upholds ten amended claims of SANUWAVE's '119 patent

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today reported that the U.S. Patent and Trademark Office (USPTO) issued a reexamination certificate upholding ten amended claims of SANUWAVE's U.S. Patent No. 6,080,119 following a third party's ex parte reexamination request.

15 Jun 2011

SANUWAVE Health raises $4,102,660 from exercise of Options

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, announces that it has raised gross proceeds of $4,102,660 from the exercise of Options that were issued as part of the sale of Units to accredited investors during 2010. The Options had an expiration date of January 31, 2011.

7 Feb 2011

Biomet Biologics completes enrollment in Recover Kit clinical trial for chronic tennis elbow

Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, LLC, has completed the required 230 subject enrollment for its Recover® Kit clinical trial. This clinical trial studies the use of the Recover® Kit device, which produces autologous platelet-rich plasma (PRP) to treat chronic tennis elbow (lateral epicondylitis).

21 Dec 2010